Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Celgene Updates Warning Labels on Thalomid

Filed May 23rd, 2013 Laurie

Celgene Inc. has notified its customers and people taking its drug Thalomid (thalidomide) of revised warnings that include potential side effects of the medication.

Health Canada has endorsed a message from the drug company that informs the public about its revised Thalomid warnings. The new warnings indicate that taking Thalomid may increase a patient’s risk of suffering acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), both of which are considered second primary malignancies. These risks were identified during an ongoing clinical trial of the drug in which it isprescribed to patients suffering from untreated multiple myeloma.

Celgene says there is a statistically significant increased risk of AML or MDS in patients with untreated multiple myeloma receiving melphalan, prednisone, and thalidomide, compared with patients treated with lenalidomide and dexamethasone.

In its communication with physicians and the public, Celgene Inc. urges doctors: “The risk of AML and MDS must be taken into account before initiating treatment with Thalomid in combination with melphalan and prednisone (MPT). Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of second primary malignancies.”

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!